Development of a new design 125I-brachytherapy seed for its application in the treatment of eye and prostate cancer

Applied Radiation and Isotopes

Volumn 67, Issue 7-8, 2009, Pages 1421-1425

  Saxena, Sanjay Kumar ^a   Sharma, S D ^a   Dash, Ashutosh ^a   Venkatesh, Meera ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

125I; Adsorption; Dose rate constant; Leachability; Ocular brachytherapy

Indexed keywords

125I; BRACHYTHERAPY; DOSE RATE CONSTANT; DOSE RATE CONSTANTS; EXPERIMENTAL CONDITIONS; LEACHABILITY; ND : YAG LASERS; NEW DESIGN; NEW SOURCES; OCULAR BRACHYTHERAPY; PROSTATE CANCERS;

ADSORPTION; PALLADIUM; RATE CONSTANTS; SILVER; TITANIUM;

NEODYMIUM LASERS;

IODINE 125; PALLADIUM; POLY(METHYL METHACRYLATE); POLYMER; SILVER; TITANIUM;

ARTICLE; BRACHYTHERAPY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; ENCAPSULATION; EYE CANCER; NEODYMIUM LASER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; TREATMENT INDICATION;

ADSORPTION; BRACHYTHERAPY; DRUG COMPOUNDING; EQUIPMENT DESIGN; EYE NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MALE; MICROSPHERES; PALLADIUM; PROSTATIC NEOPLASMS; RADIATION DOSAGE; SILVER;

EID: 66149101340     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.02.040     Document Type: Article

References (16)

1. AERB SS-3 (Rev-1), 2001. Testing and Classification of Sealed Radioactive Sources. A Publication of Atomic Energy Regulatory Board of India.
2. 125I interstitial brachytherapy seed. Med. Phys. 29 (2002) 709-715
3. Bice W., Prestidge B., Grimm P., Friedland J., Feygelman V., Roach M., Prete J., Dubois D., and Blasko J. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 41 (1998) 921-927
4. Bownes P., and Flynn A. Prostate brachytherapy: a review of current practice. J. Radiotherapy Practice 4 (2004) 86-101
5. Bret H.H., Robert E.W., and James M.H. Comparison of I-125 sources used for permanent interstitial implants. Med. Phys. 28 (2001) 671-682
6. Finger P.T. Radiation therapy for choroidal melanoma. Surv. Opthalmol. 42 (1997) 215-232
7. 0 reduction. J. Appl. Electrochem. 1 4 (1971) 283-291
8. Johnson M., Colonias A., Parda D., Trombetta M., Gayou O., Reitz B., and Miften M. Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage I non-small cell lung cancer. Phys. Med. Biol. 52 (2007) 1237-1245
9. Karaikos P., Papagiannis P., Sakelliou L., Anagnostopopoulos G., and Baltas D. Monte Carlo dosimetry of select seed I-125 interstitial brachytherapy seed. Med. Phys. 28 (2001) 1753-1760
10. 125I source. Med. Phys. 26 (2000) 1275-1280
11. 125I on silver wire as matrix for brachytherapy for the treatment of eye and prostate cancer. Appl. Radiat. Isot. 57 (2002) 359-367
12. Monge M.R., Nag S., Nieroda C., and Martin E.W. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the lever. Cancer 85 6 (1999) 1218-1225
13. Nath R., and Chen Z.J. Silver fluorescent X-ray yield and its influence on the dose rate constant for nine low-energy brachytherapy source models. Med. Phys. 34 10 (2007) 3785-3793
14. Perez C.A., Grisby P.W., and Williamson J.F. Clinical applications of brachytherapy. In: Perez C.A., and Brady L.W. (Eds). I: Low Dose Rate in Principles and Practice of Radiation Oncology. third ed (1997), Lippincott-Raven, Philadelphia 487-559
15. 125I radioactive sources suitable for treatment of ocular and prostate cancers. Appl. Radiat. Isot. 64 (2006) 441-447
16. Sharma S.D., Basu M., Shanta A., Selavam Palani T., Tripathi U.B., and Bhatt B.C. Dosimetry parameters of BARC OcuProsta I-125 seed source. Aus. Phys. Eng. Sci. Med. 28 1 (2005) 14-20